Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:08:03.884Z.
Consensus retrieved: 2026-10-06T12:36:08.243Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:08:03.884Z.
Quote observation: 2026-10-06T16:05:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5055be797218969f54b4ba6f74251721a3824cc5143f897fa443291008c6f72f
Forward PE Ratio (N/A) = Dated Quote Price ($1.05) / Consensus Forward EPS ($-0.37)
FORWARD PE RATIO
N/A
iBio, Inc.
Market Cap
$67.84M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| iBio, Inc. (IBIO) | $67.84M | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $67.38M | 48.50 |
| Fortress Biotech, Inc. (FBIO)vs › | $68.43M | N/A |
| RenovoRx, Inc. (RNXT)vs › | $66.45M | N/A |
| Cingulate Inc. (CING)vs › | $66.00M | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $70.39M | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.71M | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.07M | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | N/A |
| InterCure Ltd. (INCR)vs › | $63.61M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-06-30
At the dated quote price of $1.05, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $-0.37 | $-0.81 – $-0.21 | 6 | n/m |
| 2028-06-30 | $-0.59 | $-0.98 – $-0.26 | 4 | n/m |
| 2029-06-30 | $-0.73 | $-1.43 – $-0.34 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
